# Extending Thioflavin T Fluorescence Probe to 2‑Ethenyl-benzothiazole Derivatives: Drug-like Quadruplex Ligands with Potent Antitrypanosomatid Activity

**Authors:** Raquel C. R. Gonçalves, Pablo Peñalver, Nina M. Allen, Efres Belmonte-Reche, Belén García-Pérez, Susana P. G. Costa, Y. Jennifer Jiang, José María Pérez-Victoria, M. Carmen Galan, M. Manuela M. Raposo, Juan Carlos Morales

PMC · DOI: 10.1021/acsinfecdis.5c00691 · ACS Infectious Diseases · 2025-11-04

## TL;DR

This study develops new drug-like compounds that bind to G-quadruplex structures and show strong antiparasitic activity against Leishmania and Trypanosoma.

## Contribution

The paper introduces 2-ethenyl-benzothiazole derivatives as potent and selective antitrypanosomatid agents with improved G4 binding.

## Key findings

- Several 2-ethenyl benzothiazole derivatives showed submicromolar activity against Leishmania and Trypanosoma parasites.
- Compound 2b exhibited exceptional potency and selectivity, outperforming existing antiparasitic drugs.
- Biophysical studies confirmed that the derivatives strongly stabilize G4 structures, surpassing Thioflavin T.

## Abstract

Thioflavin T (ThT) is a well-established fluorescence probe with selectivity for G-quadruplex (G4) structures. Over the past few years, G4 ligands have emerged as promising candidates for the development of antiparasitic agents. Building on this concept, we explored extending ThT’s benzothiazole scaffold by introducing various 2-ethenyl aromatic and heteroaromatic moieties, aiming to enhance G4 binding affinity and potential therapeutic effect. A series of benzothiazolium derivatives were synthesized and evaluated for their antiproliferative and antiparasitic activity. Several 2-ethenyl benzothiazole derivatives showed submicromolar activity against Leishmania spp. and Trypanosoma brucei parasites, with up to 200-fold selectivity over MRC-5 human lung fibroblasts. Notably, compound 2b demonstrated remarkable potency, with an IC50 of 0.48 nM and a selectivity index of 46,151 against Leishmania major amastigotes, and an IC50 of 0.019 nM and a selectivity index of 79,206 against T. brucei. In fact, compound 2b demonstrated superior efficacy and selectivity in comparison to the clinically used drugs suramin, fexinidazole, miltefosine, and amphotericin B. Biophysical studies revealed that all tested derivatives exhibited significant G4 stabilization, surpassing ThT. Location of compound 2b inside the nucleus and the kinetoplast, as well as partially in the mitochondria, opens up the possibility of 2b acting against the parasite through binding to G4.

## Linked entities

- **Chemicals:** Thioflavin T (PubChem CID 16953), suramin (PubChem CID 5361), fexinidazole (PubChem CID 68792), miltefosine (PubChem CID 3599), amphotericin B (PubChem CID 1972)
- **Species:** Leishmania major (taxon 5664), Trypanosoma brucei (taxon 5691)

## Full-text entities

- **Chemicals:** fexinidazole (MESH:C038307), amphotericin B. (MESH:D000666), miltefosine (MESH:C039128), suramin (MESH:D013498), 2-Ethenyl-benzothiazole Derivatives (-), benzothiazole (MESH:C005465), ThT (MESH:C009462), G4 (MESH:D004003)
- **Species:** Leishmania major (species) [taxon 5664], Homo sapiens (human, species) [taxon 9606], Trypanosoma brucei (species) [taxon 5691]
- **Cell lines:** MRC-5 — Homo sapiens (Human), Finite cell line (CVCL_0440)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12643529/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12643529/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12643529/full.md

---
Source: https://tomesphere.com/paper/PMC12643529